0001415889-24-016569.txt : 20240612 0001415889-24-016569.hdr.sgml : 20240612 20240612200006 ACCESSION NUMBER: 0001415889-24-016569 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240611 FILED AS OF DATE: 20240612 DATE AS OF CHANGE: 20240612 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blumenkranz Mark S. CENTRAL INDEX KEY: 0001614869 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 241039759 MAIL ADDRESS: STREET 1: C/O 1LIFE HEALTHCARE, INC. STREET 2: ONE EMBARCADERO CENTER, SUITE 1900 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KALA BIO, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 FORMER COMPANY: FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20091223 4 1 form4-06122024_080602.xml X0508 4 2024-06-11 0001479419 KALA BIO, Inc. KALA 0001614869 Blumenkranz Mark S. C/O KALA BIO, INC. 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 true false false false 0 Common Stock 2024-06-11 4 A 0 1400 0 A 13091 D Common Stock 168454 I See footnote Common Stock 1276 I See footnote Stock Option (right to buy) 6.18 2024-06-11 4 A 0 3150 0 A 2034-06-10 Common Stock 3150 3150 D Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. Includes 6,615 unvested RSUs. These securities are held directly by Lagunita Biosciences, LLC ("Lagunita"). The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are held directly by Garland Investments, L.P. ("Garland"). The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. /s/ Mary Reumuth, Attorney-in-Fact 2024-06-12